How drugs and genes controlling REV-ERBα and REV-ERBβ affect the growth of immune dendritic cells

Both REV-ERBα and REV-ERBβ expression is upregulated during the differentiation of bone marrow derived dendritic cells.

• Dendritic cells play a crucial role in linking innate and adaptive immune responses.
• BMDCs lacking REV-ERBα and REV-ERBβ show increased maturation markers and proinflammatory cytokines.
• Treatment with a REV-ERB-specific agonist reduces the expression of maturation markers and proinflammatory cytokines.
• REV-ERBs may function as negative regulators in dendritic cell development and activation.
• Pharmacological targeting of REV-ERB activity could potentially adjust dendritic cell activation status.

Simplified